Methods of treating breast cancer that overexpress AKT kinase
OwnerJin Q. Cheng, Said M. Sebtiinventors
Life of this patent
Estimating the term…
Abstract
This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
Claims22
A method for treating breast cancer in a patient in need thereof comprising:
- (a) obtaining a biological sample of a breast cancer or tumor from the patient;
- (b) determining whether the breast cancer or tumor overexpresses AKT kinase and/or has hyper-phosphorylated AKT and/or hyper-activated AKT;
- and
- (c) if the breast cancer or tumor has hyper-phosphorylated AKT and/or hyper-activated AKT, administering to said patient a therapeutically effective amount of triciribine (TCN) or triciribine-phosphate phosphate (TCN P) in a range of 0.5 to 350 mg/m2 in combination or alternation with at least one additional chemotherapeutic agent selected from the group consisting of taxol, paclitaxel, taxotere, docetaxel, cyclophosphamide, and doxorubicin.
A method for identifying and treating a patient having a breast cancer tumor or a cell with enhanced sensitivity to triciribine (TCN) comprising the steps of:
- (a) determining whether the patient has a tumor or a cancer cell with enhanced sensitivity to TCN by:
- (i) obtaining a biological sample of the breast tumor or cell from the patient;
- (ii) measuring the expression level of AKT kinase of the sample;
- (iii) comparing the expression level of AKT kinase of the sample to the expression level in a control tissue wherein a 1.5 greater fold expression of Akt in the sample compared to the control tissue is indicative of a patient having a tumor or cancer cell with enhanced sensitivity to TCN;
- and
- (b) if the sample has enhanced sensitivity to TCN, administering to the patient TCN or TCN-P in a range of 0.5 to 350 mg/m2.
A method for treating breast cancer in a patient in need thereof comprising:
- (a) obtaining a biological sample of a breast cancer or tumor from the patient;
- (b) determining whether the breast cancer or tumor overexpresses AKT kinase and/or has hyper-phosphorylated AKT and/or hyper-activated AKT;
- and
- (c) if the breast cancer or tumor has hyper-phosphorylated AKT and/or hyper-activated AKT, administering to said patient a therapeutically effective amount of triciribine (TCN) or triciribine-phosphate phosphate (TCN P) in a range of 0.5 to 350 mg/m2.
Dependencies are inferred from the claim text.